{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"Estimate the one-year disease-free survival (DFS) for research participants who receive this study treatment. DFS is defined as time from transplantation to the occurrence of relapse or death due to relapse. Patients who are alive at the time of analysis or die due to other causes will be censored at the time of their events. The estimated percentage of participants with DFS at one-year post-transplantation is reported using Kaplan-Meier analysis.","groups":[{"description":"Participants meeting eligibility criteria and who underwent haploidentical stem cell transplantation with systemic chemotherapy and antibodies, including Fludarabine, Thioplex®, L-phenylalanine mustard, mycophenolate mofetil, CellCept®, Rituxan™, Muromonab (prior to January 2010) or Alemtuzumab (beginning January 2010), Cyclophosphamide, Anti-thymocyte globulin (Rabbit), and G-CSF.","id":"OG000","title":"High-Risk Hematologic Malignancies"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"One year post-transplant","title":"Disease-Free Survival (DFS)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}